Related Experiment Video

Updated: Mar 19, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.6K

Prevalence and Resolution of Lupus Anticoagulant in Children

Chandra Kallanagowdar1, Aman Chauhan2, Mora V Puertolas3

  • 1Department of Hematology/Oncology, Louisiana State University Health Sciences Center/Children's Hospital, New Orleans, LA.

Ochsner Journal
|June 16, 2016
PubMed

Insights

Lupus anticoagulant (LA) screening is recommended for children with prolonged partial thromboplastin time (PTT), even without a bleeding history. This study found a 21% incidence of LA in pediatric patients with abnormal PTT.

Area of Science:

  • Pediatric Hematology
  • Autoimmune Disorders
  • Coagulation Studies

Background:

  • Lupus anticoagulant (LA) autoantibodies inhibit phospholipid-dependent reactions.
  • Limited data exists on LA incidence and prevalence in pediatric populations.
  • LA can be associated with bleeding abnormalities and complications.

Purpose of the Study:

  • Determine the incidence and complication risk of LA in children with abnormal PTT.
  • Identify clinical signs, symptoms, and medical history linked to LA.
  • Correlate laboratory findings of bleeding abnormalities with clinical bleeding symptoms.

Main Methods:

  • Retrospective analysis of 112 pediatric patients with abnormal coagulation profiles or bleeding history.
  • Patients were referred to a specialized Hematology/Oncology department.
  • Follow-up continued until partial thromboplastin time (PTT) normalized.

Main Results:

  • Preliminary incidence of LA was 21% in the study population.
  • Resolution of LA correlated with PTT correction in 90% of patients.
  • LA was identified in children presenting with abnormal coagulation profiles.

Conclusions:

  • Screening for LA is recommended in children with prolonged PTT.
  • LA evaluation can be beneficial even with a negative bleeding history.
  • This approach may reduce extensive and costly blood workups.
Abstract

Keywords:
Antibodies–anticardiolipinlupus coagulation inhibitorlupus erythematosus–systemicpediatrics

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
360
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
456
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
652
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
426
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313